RZRuslan V. Zhurikov

Ruslan V. Zhurikov

*This is an algorithmically generated author record based on publicly available information.

Ruslan V. Zhurikov has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Study of the effect of 1-({4-[(2,4-dichlorobenzoyl)amino]phenyl}sulfonyl-(2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid (GGM-27) on tumor growth and survival in BALB/c mice bearing ACATOL colon adenocarcinoma in comparison with doxorubicin

    by L. P. Kovalenko, R. V. Zhurikov, O. S. Grigorkevich, E. A. Ivanova, A. G. Vasilchuk, G. V. Mokrov, A. K. Zhanatayev, T. A. Gudasheva, V. L. Dorofeev, Л. П. Коваленко, et al.

    Introduction. Matrix metalloproteinases (MMPs) belong to the family of zinc-dependent endopeptidases capable of degrading the main components of extracellular matrix proteins that form the basis of connective tissue; they are also involved in many pathological processes in the body. MMP-2 is actively expressed in lung cancer tissues, while MMP-2 and MMP-9 play a significant role in the development of colorectal cancer. Objective. To evaluate the effect of 1-({4-[(2,4-dichlorobenzoyl)amino]phenyl}sulfonyl-(2S,4R)-4-hydroxypyrrolidine-2 carboxylic acid (GGM-27) on tumor growth and survival in BALB/c mice using the AKATOL colon adenocarcinoma model. Materials and methods. AKATOL colon adenocarcinoma was implanted subcutaneously into the axillary region of male BALB/c mice at a dose of 1×10⁶ cells. From day 2 to day 15 of tumor development, GGM-27 was administered intraperitoneally (i.p.) at doses of 1 mg/kg and 10 mg/kg. Doxorubicin was used as a reference drug, administered at a dose of 5 mg/kg i.p. on days 2 and 4 of tumor development. The antitumor activity of GGM-27 was assessed by tumor growth inhibition (TGI) and lifespan extension (LSE). Results. After a 14-day course of i.p. administration of GGM-27 at a dose of 1 mg/kg, TGI was 72.8 % on day 21 of the experiment and 71 % on day 28. After i.p. administration of GGM-27 at a dose of 10 mg/kg, TGI was 63 % on day 21 and 56% on day 28. LSE after a course of GGM-27 at a dose of 10 mg/kg was 24 %. After two i.p. administrations of doxorubicin at a dose of 5 mg/kg, TGI was 82 % on day 21 and 69 % on day 28; however, two of the 12 animals died due to drug toxicity. Conclusions. Administration of 1-({4-[(2,4-dichlorobenzoyl)amino]phenyl}sulfonyl-(2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid at a dose of 1 mg/kg caused TGI. On day 21 of the experiment, with GGM-27 administration, TGI was 73 %, and on day 28, TGI was 71 %.

  • Open Access

    Efficacy of 2-isobutyl-4,6-dimethyl-5-oxypyrimidine in monotherapy and in combination with doxorubicin on AKATOL colon cancer in mice

    by Ruslan V. Zhurikov, Журиков Руслан Владимирович, Larisa P. Kovalenko, Коваленко Л. П., Elena A. Ivanova, Иванова Е. А., Anastasia G. Vasilchuk, Васильчук А. Г., Larisa G. Kolik, Колик Л. Г., et al.

    Background. Compounds capable of suppressing inflammation and modulating the antitumor immune response may enhance the effectiveness of cytostatic therapy. In this regard, the strategy of combined use of 2-isobutyl-4,6-dimethyl-5-oxypyrimidine with classical chemotherapy drugs is of particular interest. Aim. Evaluation of 2-isobutyl-4,6-dimethyl-5-oxypyrimidine (base SNK-411 and salt SNK-578) per se or with doxorubicin on tumor growth inhibition and survival in the murine AKATOL colon adenocarcinoma model. Materials and methods. Antitumor activity of 2-isobutyl-4,6-dimethyl-5-oxypyrimidine was studied in tests on BALB / c mice using the AKATOL colon adenocarcinoma model. A standard graft of 1 × 106 AKATOL tumor cells was administered to each mouse. Starting on day 2, mice received treatment with SNK-578 (10 mg / kg, intraperitoneal) or SNK-411 per os (25 mg / kg) or their combinations with doxorubicin daily. A positive control group received doxorubicin (5 mg / kg, intraperitoneal) on days 2 and 4. The endpoints for assessing antitumor activity were the percentage of tumor growth inhibition (TGI) and increase in lifespan. Results. Monotherapy with SNK-411 and SNK-578 showed high efficacy (TGI ~74 % on day 21). Doxorubicin showed similar efficacy (inhibition of tumor growth 82 %), however, in this group, the death of 2 out of 12 animals was recorded. The combination therapy surpassed the monotherapy with doxorubicin in terms of tumor growth suppression and did not cause the death of animals. The increase in lifespan in the SNK-411 and SNK-578 groups was 31 and 33 %, respectively. Conclusion. Base SNK-411 and salt SNK-578 show antitumor activity and synergize with doxorubicin, reducing its toxicity. These results corroborate earlier data from cervical cancer RSHM-5 and Lewis lung carcinoma models.

  • Effect of 2-isobutyl-4,6-dimethyl-5-oxypyrimidine hydrochloride with antitumor activity on the cell cycle phases in the Jurkat model

    by R. V. Zhurikov, A. A. Sokolovskaya, L. P. Kovalenko, L. G. Kolik

    Introduction . Evaluating the ability of novel antitumor compounds to arrest specific phases of the cell cycle is a key step in their preclinical characterization for chemotherapeutic application. The synthesized compound 2-isobutyl-4,6-dimethyl-5-oxypyrimidine in salt (CHK-578) form, have demonstrated antitumor and antimetastatic efficacy in models of Lewis lung carcinoma and B16 melanoma. Objective. To evaluate the effects of CHK-578 in comparison with doxorubicin (DOX) on the cell cycle phases of Jurkat cells. Materials and Methods . Experiments were conducted on Jurkat cell line (a lymphoblastic leukemia cell line). After 24and 48-hour incubation with DOX (10 -5 M) or CHK-578 (10 -4 M and 10 -5 M), the cells were stained with a propidium iodide solution containing RNase A, followed by cell quantification using flow cytometry. Results. Culturing Jurkat cells with DOX or CHK-578 (10 -4 M) for 48 hours revealed an increase in the proportion of cells in the G₁ phase of the cell cycle and a decrease in the proportion of cells in the S phase. Conclusions. Using the Jurkat cell line culture, it was established that CHK-578, similar to DOX, affects DNA synthesis in the S phase of the cell cycle. The obtained data confirm the possibility of enhancing the antitumor effect with the combined use of CHK-578 and DOX, which was previously observed in in vivo model experiments.

  • Open Access

    Treatment outcome in a patient with triple-negative breast cancer using adoptive immunotherapy

    by E. V. Abakushina, R. V. Zhurikov, S. A. Roumiantsev

    Breast cancer (BC) is the most common malignant neoplasm in women. Adoptive immunotherapy (AIT) using activated lymphocytes is a promising approach to the treatment. Patient O., 63 years old, was diagnosed in October 2021 with infiltrating ductal carcinoma of left breast T3NxM0, Grade 2, triple negative subtype, CHEK-2 associated. According to PET/CT, the tumor size was 43 ´ 21 mm. AIT with cytokineinduced killers (CIK) was administered. In order to produce CIK, mononuclear cells were isolated from peripheral blood and cultured in presence of cytokines for 10-14 days. AIT was performed by intradermal injections paravertebrally once a week up to present date. In the course of AIT, PET/CT, MRI, ultrasound and immunophenotyping of blood lymphocytes were performed. 7 courses of AIT were administered since November 2021. Six months after starting AIT, positive dynamics was noted as proven by PET/CT data: a decreased activity of tumor in left mammary gland (LMG) with SUVmax of 16.76 (previously, SUVmax 28.74) while maintaining the size. Moreover, previously identified signs of osteoblastic changes in spine at Th12 level were not detected. According to PET/CT results in November 2022, a slight increase in size of LMG formation up to 49 ´ 35 mm (SUVmax, 16.82) was noted, while an area of the radiopharmaceutic accumulation was detected in the body of the L2 vertebra and sigmoid colon. Radical mastectomy was performed In early December 2022. The tumor size was 5.3 cm, the resection margin was free of tumor cells, metastases were found in 2 of 14 lymph nodes. In order to prevent relapse, AIT was continued: 790 million CIKs were administered during a year. According to MRI data in March 2023, there was no relapse. In August 2024, the lesion in the ileum still remains. The median overall survival of patients with TNBC is 10.2 months. The average life expectancy of patients with metastases is less than 1 year. In the presented clinical case, 34 months have passed since the diagnosis, thus indicating an effective combination of AIT with surgical treatment. We conclude that AIT CIKs has a high potential for treatment of patients with TNBC.

  • Open Access

    Changes in the functional activity of NK cells in cancer patients during in vitro cultivation

    by Moscow Limited Liability Company “Teсon Medical Devices”, N.V. Grishchenko, K.D. Balysheva, R.V. Zhurikov, E.V. Abakushina

    Функциональная активность НК-клеток у пациентов с онкологическими заболеваниями при культивировании in vitro

  • Open Access

    Anticancer activity of tyrosine kinase TrkA receptors antagonist GK-1 in experiment on mice with mammary gland adenocarcinoma Ca755

    by L. P. Kovalenko, P. Yu. Povarnina, R. V. Zhurikov, S. V. Alekseeva, L. G. Kolik, T. A. Gudasheva, A. D. Durnev, V. I. Dorofeev

    The aim of this study was to evaluate the effect of original tyrosine kinase TrkA antagonist GK-1 on tumor growth, median lifespan and hematological parameters in experiment on female mice C57Bl/6 with mammary gland adenocarcinoma Ca755. 14-day intraperitoneal administration of GK-1 at a dose of 10 mg/kg resulted in a significant tumor growth inhibition (TGI) on the 9th, 15th, and 21st day of adenocarcinoma Ca755 development. TGI on the 21st day was 60 %. Administration of GK-1 at doses of 1 mg/kg and 10 mg/kg significantly increased median lifespan of experimental animals by 53 % and 47% respectively. Median lifespan was calculated using the Kaplan-Meier survival analysis. Median lifespan of active control group was 18 days, in groups that received GK-1 at doses of 1 mg/kg and 10 mg/kg median lifespan was 30 days. Hematological parameters of experimental animals were not altered by administration of GK-1. Double injection of the doxorubicin on the 2nd and the 4th day of tumor development at dose of 4 mg/kg resulted in TGI by 73% on the 21st day of experiment, increase in lifespan was 58% and median lifespan was 31 days. Our data show that further investigation of the antitumor activity of GK-1 may bring promising results.

  • Open Access

    Phenotypic characteristics of natural killer cells after their generation and activation in vitro

    by E. V. Abakushina, R. V. Zhurikov, K. D. Balysheva, M. V. Beketova, S. A. Rumyantsev

    The development of new effective methods for in vitro activation and culturing of natural killer (NK) cells led to advances in adoptive cancer immunotherapy. Our aim was to evaluate expression of activation markers on natural killer cells after cultivation and activation in vitro using flow cytometry. Peripheral blood mononuclear cells were isolated from heparinized blood of 10 donors in a density gradient and were cultivated in RPMI-1640 medium (Sigma-Aldrich, Germany) supplied with IL-2 and TMDK562-15 feeder cells for 14 days. Phenotyping of the NK cells was carried out using an Image Stream MkII (Luminex) flow cytometer. We used a cytometry panel containing 10 monoclonal antibodies against СD45, СD3, СD56, СD16, and against cell activation markers, i.e., CD38/HLA-DR/CD25 (BD Biosciences). Cytotoxic activity of the donor-derived NK cells was tested towards cancer cell lines AsPC-1, A-549, MDA-MB-231 and PC-3 on 14th day of cultivation. The effector-to-target ratios were 5:1 and 10:1. The target cells were exposed to effector cells for 12 hours. Statistical analysis was performed using MS Excel 2016, TIBCO STATISTICA 13. Prior to cultivation, the percentage of natural killer cells in mononuclear cells was 12%. Of those, activation markers (CD38/HLA-DR/CD25) were expressed, accordingly, on 7.6%, 0.7%, 0% cells, Cultivation of mononuclear cells for 14 days resulted in activation and expansion of distinct lymphocyte subpopulations. NK cell counts increased 390-fold on 14th day of cultivation, with percentage of natural killers reaching 86.5%. On the 14th day of cultivation, expression levels of activation markers (CD38/HLA-DR/CD25) were 34.7%, 36.5%, 5%, accordingly. Studying the cytotoxic activity of NK cells against different cancer cell lines showed that, after 12-h incubation of activated cells with target cells, 100% of cancer cells have been lysed. The donor cells were viable by 98%. After 7 days of cultivation, the cell viability decreased to 81%; at the end of cultures, their viability was 95%. The suggested cultivation technique for mononuclear cells cause an increase of proliferative activity and expression of activation markers of NK cells, thus allowing to maintain high viability of the cell population. High functional activity of cultured NK cells was confirmed in cytotoxicity tests against cancer cells.

  • Open Access

    Effect of GK-1 NGF Loop 4 Dipeptide Mimetic on tumor growth and metastasis of Lewis lung carcinoma in experiment on male C57BL/6 mice

    by L. P. Kovalenko, R. V. Zhurikov, P. Yu. Povarnina, A. V. Tarasiuk

    Article describes results of study of antitumor and antimetastatic action of dipeptide mimetic of the nerve growth factor amide N-monosuccinyl-L-glutamyl-L-lysine (compound GK-1) in comparison with gemcitabine. Two injections of gemcitabine in total dose of 100 mg/kg resulted in significant tumor growth inhibition by 60–61% on 7th, 9th and 15th days of tumor development. Course administration of GK-1 in doses of 10 mk/kg from 2nd to 15th day of tumor development resulted in significant tumor growth inhibition by 57,8 %. Metastasis inhibition index (MII) of gemcitabine was 75,8 %. MII of GK-1 in doses of 10 mg/kg or 30 mg/kg was 44,9 % and 47,7 % accordingly. It was shown that GK-1 in studied range of doses exerts antimetastatic activity.


  • Open Access

    Anti-inflammatory properties of 5-hydroxypirimidine derivatives on the model of CFA-induced paw and ankle joint edema in rats

    by R. V. Zhurikov, L. P. Kovalenko, S. V. Nikitin

    Anti-inflammatory potency of 5-hydroxypyrimidine derivatives SNK-411 (2-isobutyl-4,6-dimethyl-5-hydroxypirimidine) and SNK-578 (hydrochloride 2-isobutyl-4,6-dimethyl-5-hydroxypirimidine) was evaluated on the model of complete Freund`s adjuvant (CFA)-induced exudative inflammation in experiment on 60 outbreed male rats weighing 180–200 g in comparison with prednisolone. Prednisolone, SNK-411 and SNK-578 were injected twice: in 24 and 2 hours in before the injection of CFA. Prednisolone was administered in dose of 10 mg/kg, SNK-411 in doses of 25 mg/kg and 40 mg/kg, SNK-578 in doses of 10 mg/kg and 25 mg/kg. Paw and ankle joint edema were registered 24 hours after subplantar injection of CFA in right hind foot. Prednisolone administration in dose of 10 mg/kg decreased paw and ankle joint edema, SNK-578 in dose of 25 mg/kg decreased exudative edema of the paw, SNK-411 in dose of 40 mg/kg decreased paw and ankle joint edema. Acquired data correlates with previously obtained results that 5-hydroxypirimidine derivatives have antiallergenic effect on the model of systemic anaphylaxis in experiment on guinea pigs.

  • Open Access

    EFFECTS OF 5-HYDROXYPYRIMIDINE DERIVATIVE ON GROWTH AND METASTASIS OF MELANOMA B16 IN C57BL/6 MICE

    by R. V. Zhurikov, L. P. Kovalenko, S. V. Nikitin, A. D. Durnev

    Introduction. Suppression of activation of an alternative immune response is promising approach of tumor immunotherapy. In this study we evaluated antitumor and antimetastatic activity of SNK-411.Objective. Evaluation of antitumor and antimetastatic activity of 5-hydroxypyrimidine derivative SNK-411 in mouse melanoma B16 model.Materials and methods. Antitumor and antimetastatic activity of the SNK-411 were studied in tests on male C57BL/6 mice using the B16-F10 melanoma model. SNK-411 was injected intraperitoneally at doses of 10 and 25 mg/kg from day 2 to day 15 of melanoma development. Doxorubicin was injected at dose of 4 mg/kg on day 2 of tumor development to act as positive control. Antitumor and antimetastatic activity were studied by calculation of tumor growth inhibition and metastasis inhibition index (MII).Results. SNK-411 at doses of 10 and 25 mg/kg and in combination with single injection of doxorubicin in dose of 4 mg/kg showed antimetastatic activity. MII in SNK-411 at 10 mg/kg dose was 72 %, at dose of 25 mg/kg was 82,9 %. The combination of 14-day course of intraperitoneal injections of SNK-411 at dose of 10 mg/kg and injection of doxorubicin 4 mg/kg revealed MII 97,1 %, in half of mice in this group metastasis were not observed on 21st day of melanoma development. All results are statistically significant. There was no significant inhibition of tumor growth in all groups.Conclusion. SNK-411 has antimetastatic activity in tests on melanoma B16 model. Further investigation is required.